Bill Christiansen

A partner in Goodwin’s Life Sciences group, Bill advises pharmaceutical, biotechnology, clean energy and medical device companies, as well as universities, non-profit research institutions and investors, with respect to complex intellectual property matters and market exclusivity strategies.

Bill specializes in patent matters, with particular emphasis on worldwide patent procurement, strategic management of patent portfolios, investment due diligence, early stage company counseling, competitive patent position analysis, and intellectual property value creation. He also advises litigation teams on technical and patent specific issues.

In addition to emphasizing a cost-effective yet dynamic intellectual property portfolio approach for his clients, Bill provides counseling to assist clients in leveraging their patent estates as true business assets consistent with their business goals. He regularly counsels both national and international clients with regard to freedom to operate opinions, invalidity and non-infringement opinions, due diligence transactions, oppositions, and reexamination proceedings. Bill has extensive experience in a variety of technologies, including biology-based clean energy, small molecule therapeutics, immunology, gene therapy, stem cell therapeutics, formulations, re-formulations, drug delivery, RNAi, miRNA, antisense, gene regulation, epigenetics, diagnostics, diagnostic and therapeutic polypeptides, polynucleotides, and antibodies, vaccines, genomics, and bioinformatics.